New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey
Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil
Read New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey by Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5623518.txt.
Introduction
Iba and co-authors propose new criteria for sepsis-induced coagulopathy in BMJ Open. Sepsis often tangles the blood's clotting system. Anticoagulant drugs may help only the right subgroup. A recent redefinition of sepsis left old scores mismatched.
The team reanalyzed a nationwide Japanese survey. It held 1,498 sepsis patients with clotting problems. All had received recombinant thrombomodulin. Three measures predicted death within 28 days. Platelet count, prothrombin time ratio, and total SOFA score carried the signal. The new SIC score combines just those three. A score of four or more flagged higher risk. Its mortality split beat the older Japanese DIC score. The inputs are routine and the math is simple. Readers get a bedside tool, plus a candidate rule for choosing anticoagulant treatment.
Catalog record
| CREATOR | Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil |
|---|---|
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey By Toshiaki Iba, Marcello Di Nisio, Jerrold H Levy, Naoya Kitamura, Jecko Thachil Published in: BMJ Open DOI: 10.1136/bmjopen-2017-017046 ABSTRACT Abstract Objective Recent clinical studies have shown that anticoagulant therapy might be effective only in specific at-risk subgroups of patients with sepsis and coagulation dysfunction. The definition of sepsis was recently modified, and as such, old scoring systems may no longer be appropriate for the diagnosis of sepsis-associated coagulopathy. The aim of this study was to evaluate prognostic factors in patients diagnosed with sepsis and coagulopathy according to the new sepsis definition and assess their accuracy in comparison with existing models. Design Retrospective analysis of the nationwide survey for recombinant human soluble thrombomodulin. Setting General emergency and critical care centres in secondary and tertiary care hospitals. Participants We evaluated the prognostic value of the newly proposed diagnostic criteria for sepsis-induced coagulopathy (SIC). A total of 1498 Japanese patients with sepsis and coagulopathy complications who were treated with recombinant thrombomodulin were analysed in this study. Main outcome measures The platelet count, prothrombin time (PT) ratio, fibrinogen/fibrin degradation products, systemic inflammatory response syndrome score and Sequential Organ Failure Assessment (SOFA) score obtained just before the start of treatment were examined in relation to the 28-day mortality rate. Results The platelet count, PT ratio and total SOFA were independent predictors of a fatal outcome in a logistic regression model. A SIC score was defined using the three above-mentioned variables with a positivity threshold of 4 points or more. The SIC score predicted higher 28-day mortality rate compared with the current Japanese Association for Acute Medicine-disseminated intravascular coagulation score (38.4%vs34.7%). Conclusion The SIC score is based on readily available parameters, is easy to calculate and has a high predictive value for 28-day mortality. Future studies are warranted to evaluate whether the SIC score may guide the decision to initiate anticoagulant therapy. Keywords: disseminated intravascular coagulation, prothrombin time, platelet count, sepsis, thrombomodulin Strengths and limitations of this studySepsis-induced coagulopathy (SIC) is the first scoring system specifically designed for coagulation disturbances in sepsis following the new Sepsis-3 definition.SIC is defined by the routine coagulation tests such as platelet count and prothrombin time ratio together with Sequential Organ Failure Assessment score.Selection bias can exist since all the subjects were treated with recombinant thrombomodulin.Evaluation of the prognostic value of the SIC sore in patients receiving no anticoagulant has not yet been performed. INTRODUCTION Shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis.1 Dhainaut et al reported that DIC is a strong predictor of mortality in patients with sepsis independent of the severity of sepsis.2 Although advances have been made in recent years in the management of septic shock leading to significant improvements in survival, less attention has been paid to the DIC component.3 4 Although diagnostic criteria exist for DIC, none were specially designed for sepsis-associated DIC5–7 that is uniquely characterised by coagulation activation with oversuppression of fibrinolysis and a high incidence of organ dysfunction.8 The objectives of diagnostic criteria should ideally be to identify a homogenous group of patients with similar pathophysiology and clinical characteristics, whose outcomes can be improved by providing specific treatment interventions.9 To reach these goals, diagnostic criteria should meet the following three conditions: (1) they should be readily available and easy to use; (2) they should enable diagnostic accuracy and (3) they should have prognostic value. Since the new definition for sepsis was announced in 2016,10 a DIC score that matches this definition and would help in identifying patients who would benefit from anticoagulant treatment is urgently needed. Therefore, the aim of this study was to evaluate prognostic factors in patients diagnosed with sepsis and coagulopathy according to the new sepsis definition and assess their accuracy in comparison with the existing models. METHODS Data collection The data set was obtained from a postmarketing survey examining recombinant human-soluble thrombomodulin (TM-α; Asahi Kasei Parma Corporation, Tokyo, Japan) performed by Asahi Kasei Pharma Corporation between May 2008 and March 201011 and kindly provided by the Japanese Society on Thrombosis and Hemostasis with permission. All of the cases treated in Japan during this period were registered in the survey. The survey was performed under the supervision of the Japanese Ministry of Health, Labour and Welfare (JMHW) and was conducted in accordance with the Declaration of Helsinki and Good Vigilance Practice and Good Post-marketing Study Practice. Since complete anonymisation of personal data was performed on data collection and the identification of each patient was not possible, the ethical committees waived the need to acquire informed consent from patients. At the time of data collection, sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine consensus definition.12 A total of 2516 Japanese patients with sepsis-associated coagulation disorder were registered in this survey; however, since the record of Sequential Organ Failure Assessment (SOFA) data was not mandatory, a complete data set was only obtained in 1498 cases, and all of these patients were analysed in this study. All patients were treated with TM-α (0.06 mg/kg/day for 6 days) by either intravenous bolus injection or intravenous infusion (diluted in 50 mL 0.9% saline) over 15 min via a catheter; the exclusion criteria were as follows: age less than 18 years, major bleeding, systemic inflammatory response syndrome (SIRS) score≦1, hypersensitivity to TM-α and pregnancy. Laboratory measurements and organ dysfunction assessments Blood samples obtained just before the initiation of anticoagulant therapy were analysed, and this data were defined as the ‘initial data’. The platelet count, fibrinogen/fibrin degradation products (FDPs) and prothrombin time (PT)-international normalisation ratio were measured in local laboratories. The Japanese Association for Acute Medicine (JAAM)-DIC score7 was calculated based on the initial (just before TM-α treatment) laboratory data and the SIRS score. Dysfunctions of the respiratory, cardiovascular, hepatic and renal systems were assessed as in the SOFA score.13 A score of 2 or more within each of these systems was defined as organ dysfunction. Statistical analysis Differences in patient characteristics between survivors and non-survivors were examined using the Fisher’s exact test or unpaired Wilcoxon signed-rank test. Then, the relationships between the 28-day mortality rate and the initial data were examined in univariate and multivariate analyses using logistic regression analysis (the enter method). The analysis was conducted using the outcome (survived, 0; died, 1) as the dependent variable and age, sex, SIRS score, platelet count, PT ratio and the proportion of various organ dysfunction as explanatory variables. The numerical values in the text and tables represent the median and IQR, unless otherwise noted. The results of the logistic regression analysis were reported as the OR, 95% CI and p values. For all the reported results, a value of p<0.05 was considered to denote statistical significance. The above-mentioned analyses were performed using JMP software, V.9.0 (SAS Institute). RESULTS Baseline characteristics Among the 1498 patients, 994 (66.4%) survived at 28 days and 504 (33.6%) died. Table 1 shows the baseline characteristics of the patients. The median age was lower and the proportion of women was larger among the survivors. No difference in the SIRS score (p=0.0556) was seen between the two groups, but the